Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA3 | P0DMS8 | 14/20 | 0.54 |
| ▸ | ADORA1 | P30542 | 10/20 | 0.54 |
| ▸ | ADORA2A | P29274 | 8/20 | 0.54 |
| ▸ | ADORA2B | P29275 | 4/20 | 0.51 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6257602 | 0.87 | AHCY (0.56) | ADORA3ADORA1ADORA2AADORA2BCYP1A2 | |
| SCHEMBL6258782 | 0.85 | ADORA3 (0.74) | ADORA3ADORA1ADORA2AADORA2BMEN1 | |
| SCHEMBL6262046 | 0.85 | ADORA3 (0.48) | ADORA3ADORA1ADORA2AADORA2B | |
| SCHEMBL6262050 | 0.85 | ADORA3 (0.48) | ADORA3ADORA1ADORA2AADORA2B | |
| SCHEMBL6262051 | 0.85 | ADORA3 (0.48) | ADORA3ADORA1ADORA2AADORA2B | |
| SCHEMBL6261537 | 0.80 | AHCY (0.57) | ADORA3ADORA1ADORA2AADORA2BCYP1A2 | |
| SCHEMBL6257595 | 0.77 | AHCY (0.57) | ADORA3ADORA1ADORA2AADORA2BCYP1A2 | |
| SCHEMBL6743033 | 0.76 | AHCY (0.56) | ADORA3ADORA1ADORA2AADORA2BCYP1A2 | |
| SCHEMBL6259472 | 0.74 | ADORA3 (0.73) | ADORA3ADORA1ADORA2AADORA2B | |
| SCHEMBL6258939 | 0.74 | AHCY (0.55) | ADORA3ADORA1ADORA2AADORA2BCYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1370568-B1 | CHEMICAL COMPOUNDS | GLAXO GROUP LTD (GB) | 2005-10-12 | — | — | EP | claimed |
| US-20040162422-A1 | adenosine derivatives having an acetylene group in the 4' position, which are adenosine A1 agonists; treating ischaemic heart disease, peripheral vascular disease or stroke or patient suffering pain, a CNS disorder, sleep apnoea or emesis | HALL ADRIAN (GB) | 2004-08-19 | — | — | US | claimed |
| EP-1370568-A1 | CHEMICAL COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2003-12-17 | — | — | EP | claimed |
| WO-2002074780-A1 | CHEMICAL COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2002-09-26 | — | — | WO | claimed |
| EP-1370568-B1 | CHEMICAL COMPOUNDS | GLAXO GROUP LTD (GB) | 2005-10-12 | — | — | EP | disclosed |
| US-20040162422-A1 | adenosine derivatives having an acetylene group in the 4' position, which are adenosine A1 agonists; treating ischaemic heart disease, peripheral vascular disease or stroke or patient suffering pain, a CNS disorder, sleep apnoea or emesis | HALL ADRIAN (GB) | 2004-08-19 | — | — | US | disclosed |
| EP-1370568-A1 | CHEMICAL COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2003-12-17 | — | — | EP | disclosed |
| WO-2002074780-A1 | CHEMICAL COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2002-09-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040162422-A1 | adenosine derivatives having an acetylene group in the 4' position, which are adenosine A1 agonists; treating ischaemic heart disease, peripheral vascular disease or stroke or patient suffering pain, a CNS disorder, sleep apnoea or emesis | ADORA1, ADORA2A, ADORA2B | ADORA3 4/4885ADORA1 1/4885ADORA2A 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.